ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • 2026 ACR/ARP PRSYM
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Disease Activity"

  • Abstract Number: 1550 • ACR Convergence 2025

    Real-World Outcomes of Anifrolumab in Systemic Lupus Erythematosus Patients at Toronto Lupus Program

    Virginia Carrizo Abarza1, Qixuan Li2, Teresa Semalulu3, Justin Smith3, Pankti Mehta4, Fadi Kharouf5, Dafna D. Gladman6, Laura Whitall Garcia7 and Zahi Touma3, 1Toronto Western Hospital - University of Toronto, Toronto, ON, Canada, 2Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, 3University of Toronto, Toronto, ON, Canada, 4University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, 5University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, 6Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, 7University Health Network, Toronto, ON, Canada

    Background/Purpose: Anifrolumab (ANI) is a human monoclonal antibody targeting the type I interferon receptor subunit 1 (IFNAR1), blocking interferon activity and reducing disease activity in…
  • Abstract Number: 2131 • ACR Convergence 2025

    Transition from Juvenile Dermatomyositis to Spondyloarthritis: A Novel Overlapping Inflammatory Phenotype

    Austen Grooms1, Ioannis Karageorgiou2, Kerry Mychaliska2 and James Birmingham3, 1William Beaumont University Hospital, Auburn Hills, MI, 2William Beaumont University Hospital, Royal Oak, MI, 3River City Rheumatology, Grand Rapids, MI

    Background/Purpose: Juvenile Dermatomyositis (JDM) is a rare inflammatory disease primarily affecting muscle, skin, and vasculature. Characterized by muscle weakness, distinctive skin lesions, and autoantibodies, it…
  • Abstract Number: 2347 • ACR Convergence 2025

    Bimekizumab Treatment Resulted in Patients with Axial Spondyloarthritis Maintaining Their Clinical Responses Over 3 Years: Results from Two Phase 3 Studies and Their Open-Label Extension

    Fabian Proft1, Désirée Van Der Heijde2, Sergio Schwartzman3, Vanessa Taieb4, Sarah Kavanagh5, Gaëlle Varkas6, Victoria Navarro-Compan7 and Xenofon Baraliakos8, 1Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 2Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Weill Cornell Medical Center, New York Presbyterian Hospital, and Hospital for Special Surgery, New York, NY, 4UCB, Colombes, France, 5UCB, Morrisville, NC, 6Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, 7Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, 8Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany

    Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease which requires optimal management.1 In clinical trials, Assessment of SpondyloArthritis international Society ≥40% improvement (ASAS40) is…
  • Abstract Number: 2654 • ACR Convergence 2025

    Discordance Between Patient and Physician Global Assessments in Early Systemic Sclerosis

    Ellen Romich1, Alexis Ogdie2, Alisa Stephens Shields2, Peter Merkel2, Jessica Alvey3, Shervin Assassi4, Elana Bernstein5, Sonali Bracken6, Flavia Castelino7, Lorinda Chung8, Luke Evnin9, Tracy Frech10, Jessica Gordon11, Faye Hant12, Monica Harding13, Laura Hummers14, Dinesh Khanna15, Kimberly Lakin11, Dorota Lebiedz-Odrobina13, Yiming Luo5, Ashima Makol16, Maureen Mayes17, Zsuzsanna McMahan18, Jerry Molitor19, Duncan Moore20, Carrie Richardson21, Ami Shah14, Ankoor Shah22, Brian Skaug23, Virginia Steen24, John VanBuren13, Elizabeth Volkmann25, Carleigh Zahn15 and Nora Sandorfi2, 1University of Pennsylvania, Media, PA, 2University of Pennsylvania, Philadelphia, PA, 3Utah Data Coordinating Center, University of Utah, Salt Lake City, UT, 4Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, 5Columbia University, New York, NY, 6Duke University Medical Center, Durham, NC, USA, Apex, NC, 7Massachusetts General Hospital, Boston, MA, 8Stanford University, Stanford, CA, 9Scleroderma Research Foundation, San Francisco, CA, 10Vanderbilt University Medical Center, Nashville, TN, 11Hospital for Special Surgery, New York, NY, 12Medical University of South Carolina, Charleston, SC, 13University of Utah, Salt Lake City, UT, 14Johns Hopkins Rheumatology, Baltimore, MD, 15University of Michigan, Ann Arbor, MI, 16Mayo Clinic, Rochester, MN, 17UT Health Houston Division of Rheumatology, Houston, TX, 18UT Health Houston, Houston, TX, 19University of Minnesota, Minneapolis, MN, 20Northwestern Memorial Hospital, Chicago, IL, 21Northwestern University, Chicago, IL, 22Duke University, Durham, NC, 23UTHealth Houston Division of Rheumatology, Houston, TX, 24Georgetown University School of Medicine, Washington, DC, 25Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA

    Background/Purpose: To determine the frequency and extent of discordance between patient and physician global assessments of disease in early systemic sclerosis and identify factors associated…
  • Abstract Number: 0409 • ACR Convergence 2025

    Discordance Between Disease Activity and Patient-Reported Outcomes in Patients with Juvenile Idiopathic Arthritis

    Julia Harris1, Leslie Favier2, Emily Fox3, Jordan Jones2, Michael Holland3, Cara Hoffart2, Maria Ibarra3 and Ashley Cooper2, 1Children's Mercy Kansas City, Overland Park, KS, 2Children's Mercy Kansas City, Kansas City, MO, 3Children's Mercy Hospital, Kansas City, MO

    Background/Purpose: Outcome assessment is essential to optimize care for patients with juvenile idiopathic arthritis (JIA). Although disease activity and patient-reported outcomes (PROs) are different measures,…
  • Abstract Number: 0495 • ACR Convergence 2025

    Effectiveness and Safety of Iguratimod with Background Methotrexate Therapy in Indian Patients with Rheumatoid Arthritis: A Randomized Double Blinded Placebo Controlled Study

    MIDHUN SAKRAVARTHY JALANATHAN1, Mehdi Ali Mirza1, Vijaya prasanna Parimi2, Seethalakshmi S1 and Tejaswini Ramineni3, 1ESIC Medical College and Hospital, Sanathanagar, Hyderabad, Telangana, India, 2ESIC Medical College and Super Specilaity Hospital, hyderabad, Telangana, India, 3Esic Medical College And Hospital, Sanathnagar, Hyderabad, Telangana, India

    Background/Purpose: Iguratimod (IGU), an oral synthetic disease-modifying antirheumatic drug (DMARD), has shown significant efficacy and safety in rheumatoid arthritis (RA) when combined with methotrexate (MTX)…
  • Abstract Number: 0608 • ACR Convergence 2025

    Strong Correlation Between SLEDAI and SLE-DAS in the Spanish Population: Assessment of Discordant Patients

    Elena Heras Recuero1, Antia Garcia Fernandez2, Cristina Gomez-Moreno3, Ivan Ferraz Amaro4, Javier Llorca5 and Miguel A. González-Gay6, 1Hospital Fundacion Jimenez Dias, Madrid, Spain, 2Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, 3Fundacion Jiménez Díaz School of Nursing, Madrid, Autonomous University Madrid, Madrid, Spain, 4Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 5CIBER Epidemiología y Salud Pública (CIBERESP) and Department of Medical and Surgical Sciences, University of Cantabria, Santander, Spain, 6Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain, and Medicine and Psychiatry Department, University of Cantabria, Santander, Spain

    Background/Purpose: Assessing disease activity in systemic lupus erythematosus (SLE) is essential for effective treatment. SLEDAI-2K uses dichotomous items, while SLE-DAS incorporates both dichotomous and continuous…
  • Abstract Number: 1310 • ACR Convergence 2025

    Naturalized Language Processing Based Extraction of Rheumatoid Arthritis Disease Activity Measures from the Electronic Health Record

    Elizabeth Park1, Iram Kamdar2, Reid Weisberg1, Andy Nguyen1, Joan Bathon3, Jon Giles4, Chunhua Weng5 and Elana Bernstein1, 1Columbia University Irving Medical Center, New York, NY, 2Columbia University Data Science Institute, New York, NY, 3Columbia University, NEW YORK, NY, 4Cedars-Sinai Medical Center, New York, NY, 5Columbia University Department of Biomedical Informatics, New York, NY

    Background/Purpose: A treat-to-target approach in rheumatoid arthritis (RA) requires intense monitoring of RA disease activity with measures such as the clinical disease activity index (CDAI).…
  • Abstract Number: 1430 • ACR Convergence 2025

    Redefining BASDAI cut-offs: implications for patients’ eligibility for initiating biologic disease-modifying antirheumatic treatment in axial spondyloarthritis

    Stylianos Georgiadis1, Lykke Ørnbjerg1, Brigitte Michelsen2, Tore K. Kvien2, Mehrdad Shoae Kazemi1, Bente Glintborg1, Anne Gitte Loft3, Rita Fonseca4, Helena Santos5, Andreas Reich6, Anne C. Regierer6, Jarno Rutanen7, Laura Kuusalo8, Gary Macfarlane9, Gareth T. Jones9, Adrian Ciurea10, Michael J. Nissen11, Bjorn Gudbjornsson12, Olafur Palsson13, Ziga Rotar14, Katja Perdan Pirkmajer15, Daniela Di Giuseppe16, Merete Hetland17 and Mikkel Ostergaard18, 1Rigshospitalet, Glostrup, Denmark, 2Diakonhjemmet Hospital, Oslo, Norway, 3Aarhus University Hospital, Aarhus, Denmark, 4Unidade Local de Saúde de Entre Douro e Vouga, Santa Maria da Feira, Portugal, 5Instituto Português de Reumatologia, Lisbon, Portugal, 6German Rheumatology Research Center, Berlin, Germany, 7Tampere University Hospital, Tampere, Finland, 8Turku University Hospital, Turku, Finland, 9University of Aberdeen, Aberdeen, United Kingdom, 10University Hospital Zurich, Zurich, Switzerland, 11Geneva University Hospital, Geneva, Switzerland, 12Landspitali University Hospital; Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 13University of Iceland, Reykjavik, Iceland, 14University Medical Centre Ljubljana, Ziri, Slovenia, 15University Medical Centre Ljubljana, Ljubljana, Slovenia, 16Karolinska Institutet, Department of Medicine Solna, Clinical Epidemiology Division, Stockholm, Stockholms Lan, Sweden, 17Copenhagen Center for Arthritis Research (COPECARE) and DANBIO, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark, 18Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, and Copenhagen Center for Arthritis Research, Center for Rheumatology, Rigshospitalet, Glostrup, Denmark

    Background/Purpose: In patients with axial spondyloarthritis (axSpA), high disease activity is a key indication for biological disease-modifying antirheumatic drug (bDMARD) initiation. The Axial Spondyloarthritis Disease…
  • Abstract Number: 1566 • ACR Convergence 2025

    Factors Associated with Patient and Physician Global Assessments in Early Systemic Sclerosis

    Ellen Romich1, Alexis Ogdie2, Peter Merkel3, Alisa Stephens Shields3, Jessica Alvey4, Shervin Assassi5, Elana Bernstein6, Sonali Bracken7, Flavia Castelino8, Lorinda Chung9, Luke Evnin10, Tracy Frech11, Jessica Gordon12, Faye Hant13, Monica Harding14, Laura Hummers15, Dinesh Khanna16, Kimberly Lakin12, Dorota Lebiedz-Odrobina14, Yiming Luo6, Ashima Makol17, Maureen Mayes18, Zsuzsanna McMahan19, Jerry Molitor20, Duncan Moore21, Carrie Richardson22, Ami Shah15, Ankoor Shah23, Brian Skaug24, Virginia Steen25, John VanBuren14, Elizabeth Volkmann26, Carleigh Zahn16 and Nora Sandorfi3, 1University of Pennsylvania, Media, PA, 2Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, 3University of Pennsylvania, Philadelphia, PA, 4Utah Data Coordinating Center, University of Utah, Salt Lake City, UT, 5Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, 6Columbia University, New York, NY, 7Duke University Medical Center, Durham, NC, USA, Apex, NC, 8Massachusetts General Hospital, Boston, MA, 9Stanford University, Stanford, CA, 10Scleroderma Research Foundation, San Francisco, CA, 11Vanderbilt University Medical Center, Nashville, TN, 12Hospital for Special Surgery, New York, NY, 13Medical University of South Carolina, Charleston, SC, 14University of Utah, Salt Lake City, UT, 15Johns Hopkins Rheumatology, Baltimore, MD, 16University of Michigan, Ann Arbor, MI, 17Mayo Clinic, Rochester, MN, 18UT Health Houston Division of Rheumatology, Houston, TX, 19UT Health Houston, Houston, TX, 20University of Minnesota, Minneapolis, MN, 21Northwestern Memorial Hospital, Chicago, IL, 22Northwestern University, Chicago, IL, 23Duke University, Durham, NC, 24UTHealth Houston Division of Rheumatology, Houston, TX, 25Georgetown University School of Medicine, Washington, DC, 26Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA

    Background/Purpose: Global assessments by patients and physicians provide unique but complementary perspectives of disease severity. This study aimed to determine the clinical and patient-reported factors…
  • Abstract Number: 2148 • ACR Convergence 2025

    Initial MRI Findings as Predictors of Disease Phenotype in Juvenile Dermatomyositis: A Comparative Study of Myositis Specific Antibodies NXP2-Positive and Myositis Specific Antibody-Negative Patients in a Large Tertiary Hospital

    Juan Torres Sanchez1, Pritish Bawa2, Andrea Ramirez1, MaiLan Nguyen3, Amit Thakral4, Xiaofan Huang1, J Herman Kan2 and Marietta De Guzman1, 1Baylor College of Medicine, Houston, TX, 2Texas Childrens Hospital, Houston, TX, 3Baylor College of Medicine, Austin, TX, 4Texas Children’s Hospital, Houston, TX

    Background/Purpose: Juvenile dermatomyositis (JDM) is the most common idiopathic inflammatory myopathy of childhood, characterized by proximal muscle weakness and distinctive cutaneous findings. Magnetic resonance imaging…
  • Abstract Number: 2349 • ACR Convergence 2025

    Classification of “Difficult-to-Manage Axial Spondyloarthritis”: A Real-World Cohort Study Evaluating the ASAS 2024 Criteria Over Time

    Gözde Sevgi Kart bayram1, Muhammed Çağrı Akdemir2, Mustafa Ekici3, Gizem Ayan4, Büşra Fırlatan Yazgan1, Erdinç Ünaldı3, Buğu Bulat1, Ali Aytuğ Kuştaş3, Ali Akdoğan5, Omer Karadağ5, Şule Apraş Bilgen1, Ali İhsan Ertenli1, Sedat Kiraz3, Umut Kalyoncu1 and Levent Kılıç1, 1Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, Turkey, 2Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey, Ankara, Turkey, 3Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, Ankara, Turkey, 4Ankara Research and Training Hospital, Ankara, Turkey, 5Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara

    Background/Purpose: The concept of difficult-to-manage axial spondyloarthritis (D2M-axSpA)[1], may vary over time. Transitions between D2M and non-D2M classifications throughout the disease course remain unclear. This…
  • Abstract Number: 2683 • ACR Convergence 2025

    Association of Genetic Risk for Pain Intensity with Longitudinal Disease Activity in Rheumatoid Arthritis

    Stevie Barry1, Katie McMenamin2, Austin Wheeler3, Bryant England3, Grant Cannon4, Brian Sauer5, Gary Kunkel6, Katherine Wysham7, Beth Wallace8, Andreas Reimold9, Gail Kerr10, Isaac Smith11, John Richards12, Iris Lee13, Rui Xiao1, Sylvanus Toikumo14, Henry Kranzler14, Rachel Kember14, Scott Damrauer14, Michael Levin14, Michael George1, Ted Mikuls3, Joshua Baker1 and Thomas Riley1, 1University of Pennsylvania, Philadelphia, PA, 2Boston Medical Center, Boston, MA, 3University of Nebraska Medical Center, Omaha, NE, 4University of Utah and Salt Lake City VA, Salt Lake City, UT, 5Salt Lake City VA/University of Utah, Salt Lake City, UT, 6University of Utah and George E Wahlen VAMC, Salt Lake City, UT, 7VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 8Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, 9Dallas VA Medical Center, Dallas, TX, 10Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 11Duke University Hospital, Durham, NC, 12Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, 13Washington University in St Louis, Saint Louis, MO, 14University of Pennsylvania / Corporal Michael J. Crescenz VAMC, Philadelphia, PA

    Background/Purpose: Guidelines recommend the use of composite scores to evaluate disease activity in RA and inform a treat-to-target approach. It is recognised that patient-reported components…
  • Abstract Number: 0425 • ACR Convergence 2025

    High Density Lipoprotein Dysfunction in Juvenile Idiopathic Arthritis as Compared to Children without Rheumatologic Disease

    Tahnee Spoden1, Samira Nazzar Romero2, Deborah McCurdy3, Alice Hoftman4, Sangmee Bae5, Jennifer Wang4, Ani Shahbazian4 and Christina Charles-Schoeman6, 1UCLA, Los Angeles, CA, 2Nemours Children's Health, Orlando, 3UCLA Medical Center, Los Angeles, CA, 4UCLA, Los Angeles, 5UCLA Rheumatology, Los Angeles, CA, 6UCLA Medical Center, Santa Monica, CA

    Background/Purpose: Cardiovascular disease remains the leading cause of mortality in patients with Rheumatoid Arthritis (RA). Normally, high density lipoprotein (HDL) acts in a cardioprotective capacity…
  • Abstract Number: 0497 • ACR Convergence 2025

    Drug Survival and Discontinuation Reasons of Eight Biological Disease-Modifying Antirheumatic Drugs in 1,182 Patients with Rheumatoid Arthritis: A Retrospective Study Using the Niigata Orthopedic Rheumatoid Arthritis Database (NOSRAD)

    Nariaki Hao and Naoki Kondo, Division of Orthopedic Surgery, Niigata University Medical and Dental General Hospital, Niigata, Japan

    Background/Purpose: To retrospectively evaluate drug survival and reasons for discontinuation of eight biological disease-modifying antirheumatic drugs (bDMARDs) in rheumatoid arthritis (RA) patients using the Niigata…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 112
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology